Suppr超能文献

利那洛肽或其他药物治疗 IBS-C 或 CIC 患者的粪便稠度对肠道运动满意度的影响:CONTOR 研究的真实世界证据。

The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications: Real-World Evidence From the CONTOR Study.

机构信息

Ironwood Pharmaceuticals Inc., Cambridge, MA.

Allergan plc, Madison, NJ.

出版信息

J Clin Gastroenterol. 2019 Nov/Dec;53(10):737-743. doi: 10.1097/MCG.0000000000001245.

Abstract

GOALS

This study aimed to characterize the impact of stool consistency on patient-reported bowel movement (BM) satisfaction in patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation, with a focus on linaclotide.

BACKGROUND

As new medications for constipation become available, understanding patients' perceptions of treatment effects may help clinicians manage patient expectations and inform clinical decision-making.

MATERIALS AND METHODS

Data were derived from the Chronic Constipation and IBS-C Treatment and Outcomes Real-world Research Platform (CONTOR) study from 2 patient-reported 7-day daily BM diaries to create a dataset of 2922 diaries representing 26,524 BMs for 1806 participants. Binary variables were created for: medication(s) used in the past 24 hours and categorization of BMs as loose or watery stools (LoWS), hard or lumpy stools (HoLS), or intermediate (neither LoWS nor HoLS). The relationship between stool consistency, medication use, and BM satisfaction was analyzed using logistic regression with SEs corrected for repeated observations.

RESULTS

BMs characterized as intermediate stools and LoWS were satisfactory more often (61.2% and 51.2%, respectively) than HoLS (19.4%). Participants who reported taking linaclotide rated a similar proportion of BMs as satisfactory when described as LoWS (65.6%) or intermediate (64.1%). Linaclotide use was associated with higher odds of BMs being reported as satisfactory compared with nonlinaclotide use (odds ratio: 1.23, P<0.05).

CONCLUSIONS

Overall, CONTOR participants were more likely to report BMs classified as LoWS or intermediate as satisfactory, versus HoLS. Participants taking linaclotide were more likely to be satisfied, particularly those reporting LoWS, versus those not taking linaclotide.

摘要

目的

本研究旨在描述粪便稠度对肠易激综合征便秘型(IBS-C)或慢性特发性便秘患者报告的排便(BM)满意度的影响,重点关注利那洛肽。

背景

随着新的便秘治疗药物的出现,了解患者对治疗效果的看法可能有助于临床医生管理患者的期望并为临床决策提供信息。

材料和方法

数据来自慢性便秘和 IBS-C 治疗及结局真实世界研究平台(CONTOR)研究,该研究使用患者报告的 2 个为期 7 天的每日 BM 日记,创建了一个包含 1806 名参与者的 2922 个 BM 日记的数据集,共 26524 个 BM。创建了两个二项变量:过去 24 小时使用的药物和粪便分类为稀便(LoWS)或水样便(HoLS)、硬便或块状便(HoLS)或中间便(既非 LoWS 也非 HoLS)。使用具有重复观察校正的 SE 的逻辑回归分析粪便稠度、药物使用与 BM 满意度之间的关系。

结果

描述为中间便和 LoWS 的 BM 更常被认为是满意的(分别为 61.2%和 51.2%),而 HoLS 仅为 19.4%。报告服用利那洛肽的参与者将 LoWS(65.6%)或中间便(64.1%)描述为满意的 BM 比例相似。与非利那洛肽使用者相比,利那洛肽使用者报告的 BM 更有可能被认为是满意的(比值比:1.23,P<0.05)。

结论

总体而言,CONTOR 参与者更有可能报告 LoWS 或中间便分类的 BM 为满意,而不是 HoLS。服用利那洛肽的参与者更有可能感到满意,特别是报告 LoWS 的参与者,而不是未服用利那洛肽的参与者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36f2/6791496/8d1e1f9d33e1/mcg-53-737-g003.jpg

相似文献

9
Episodic nature of symptoms in irritable bowel syndrome.肠易激综合征症状的发作性特征。
Am J Gastroenterol. 2014 Sep;109(9):1450-60. doi: 10.1038/ajg.2014.181. Epub 2014 Jul 1.

本文引用的文献

1
What Is New in Rome IV.罗马IV中有哪些新内容。
J Neurogastroenterol Motil. 2017 Apr 30;23(2):151-163. doi: 10.5056/jnm16214.
3
Bowel Disorders.肠道疾病
Gastroenterology. 2016 Feb 18. doi: 10.1053/j.gastro.2016.02.031.
9
Systematic review: impact of constipation on quality of life in adults and children.系统评价:便秘对成人和儿童生活质量的影响。
Aliment Pharmacol Ther. 2010 May;31(9):938-49. doi: 10.1111/j.1365-2036.2010.04273.x. Epub 2010 Feb 20.
10
Risk factors for chronic constipation and a possible role of analgesics.慢性便秘的风险因素及镇痛药的潜在作用。
Neurogastroenterol Motil. 2007 Nov;19(11):905-11. doi: 10.1111/j.1365-2982.2007.00974.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验